美國的麻醉劑市場:各類藥物，各給藥途徑，各用途，各終端用戶，各地區，機會，預測，2018年～2032年

美國麻醉藥市場規模預計將從 2024 年的 24.5 億美元增長到 2032 年的 34.2 億美元，在 2025-2032 年預測期內的複合年增長率為 4.23%。市場的成長受到癌症和心血管疾病發病率上升、整容手術需求增加、國內主要製藥公司推出新產品以及新產品發布數量增加等因素的推動。美國疾病管制與預防中心估計，美國每 40 秒就會有一人心臟病發作。

門診手術和當日手術的增加推動了美國麻醉市場的成長。由於手術和麻醉程序的改進，許多手術現在可以在幾個小時內完成。因此，國內對短效、快速恢復的藥物的需求激增，特別是那些術後併發症較少、能確保患者儘早出院的藥物。

另一方面，門診治療在全國各城市地區越來越受歡迎，尤其是在醫療基礎設施發達且有保險的地區。此外，外科醫生和麻醉師傾向於使用丙泊酚等靜脈注射藥物或七氟烷等吸入藥物。

本報告提供美國的麻醉劑市場相關調查，提供市場概要，以及各類藥物，各給藥途徑，各用途，各終端用戶，各地區趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 美國的麻醉劑市場預測，2018年～2032年

• 市場規模分析與預測
• 市場佔有率分析與預測
• 2024年市場地圖分析
  • 各類藥物
  • 各給藥途徑
  • 各用途
  • 各終端用戶
  • 各地區

第5章 價值鏈分析

第6章 波特的五力分析

第7章 大環境分析

第8章 價格分析

第9章 市場動態

• 市場促進因素
• 市場課題

第10章 市場趨勢與發展

第11章 臨床試驗概要

第12章 競爭情形

• 前五名市場領導的競爭矩陣
• 前五名參與企業的SWOT分析
• 前10名市場主要企業的形勢
  • Baxter International Inc.
  • AstraZeneca Pharmaceuticals, LP
  • AbbVie Inc.
  • B. Braun Medical Inc.
  • Fresenius USA, Inc.
  • Hospira Inc.
  • Pfizer Inc.
  • Aspen Pharmacare Holdings Limited
  • Hikma Pharmaceuticals USA Inc.
  • Novartis AG

第13章 策略性建議

第14章 關於調查公司·免責聲明

United States anesthesia drugs market is projected to witness a CAGR of 4.23% during the forecast period 2025-2032, growing from USD 2.45 billion in 2024 to USD 3.42 billion in 2032. The growth of the market is boosted by the rising incidences of cancer and cardiovascular diseases, increasing demand for surgical cosmetic procedures, the introduction of new products by leading pharmaceutical companies in the country, and increasing the release of new products. According to the estimates of the United States Centers for Disease Control and Prevention, every 40 seconds, one person has a heart attack in the United States.

The increase in outpatient and same-day surgical procedures is significantly driving the growth of the United States anesthesia drugs market. Many of these operations can be performed within a few hours because of surgical and anesthetic procedures improvements. Thus, the demand for short-acting and fast-recovery medications has surged in the country, especially those that result in fewer post-operative complications and ensure early discharge for the patients.

Meanwhile, ambulatory care is gaining popularity in various urban settings across the country, especially in locations with a strong healthcare infrastructure and supportive insurance coverage. Additionally, surgeons and anesthesiologists tend to favor intravenous agents such as propofol or inhalation agents, namely sevoflurane, which have a rapid onset and offset effect.

Expansion of the Aging Population Boosts Market Demand

The growth of the elderly population significantly contributes to the increasing prevalence of age-related diseases and disorders, including osteoarthritis, heart diseases, and cancer. These conditions usually require surgical intervention, bolstering the demand for anesthesia drugs. The geriatric population is also more vulnerable to injuries due to a lack of coordination and decreased bone density, further augmenting the market's demand. According to estimates from the Population Reference Bureau, the number of Americans who are 65 or older is estimated to increase to 82 million by 2050. Meanwhile, the older population is also affected by osteoarthritis, which results in substantial demand for joint replacement surgeries, including hip and knee replacement, which require general anesthesia.

Increasing Approvals from Regulatory Bodies Support Market Expansion

Rising product approvals from regulatory bodies such as the United States Food and Drug Administration (US FDA) are supporting the market's expansion as these approvals ensure that the new products that are launched in the market meet the efficacy and safety standards that are in place, increasing trust among patients and healthcare professionals. Additionally, regulatory approval also encourages pharmaceutical companies to invest in innovations, allowing them to introduce new formulations and delivery systems.

For instance, in March 2023, Lupin Limited's alliance partner Caplin Steriles Limited received approval from the US FDA for its abbreviated new drug application (ANDA) to market Zemuron Bromide injection's generic version. Such approvals are allowing the pharma companies to expand their customer base and also encourage them to invest in research and development activities.

Hospitals Account for Significant Share of the Market

The dominance of hospitals in the market can be attributed to the presence of specialized surgical teams, advanced patient monitoring equipment, and anesthesiologists, among others, to ensure that patients are provided with high-quality treatment and care. Additionally, the increasing construction of surgical hospitals across the country is further propelling the demand for anesthesia drugs across hospitals. For instance, in August 2024, the North Carolina Surgical Hospital opened after five years of construction. The project costed USD 425 million, and the new hospital contains twenty-six surgical suites, including hybrid spaces. The hospital offers advanced treatments such as burn care, neurosurgery, and transplants, some of which are unavailable elsewhere in the state. Designed with state-of-the-art technology, the hospital has the capacity to grow and adapt according to future requirements.

Cancer Expected to Witness Significant Growth

Over the forecast period, the segment is expected to witness significant growth due to the increasing prevalence of cancer and heavy reliance on complex surgical procedures for treating a wide range of cancer cases. According to estimates from the American Cancer Society, approximately 2,041,910 new cancer cases are estimated to be reported in the United States in 2025. The treatment procedures often involve complex surgeries, including reconstructive surgeries, organ removal, and tumor resection. All these procedures heavily rely on effective anesthesia management in order to optimize the treatment outcomes and ensure the safety of the patients. Thus fueling the market's demand and supporting the segment's growth.

Future Market Scenario (2025-2032F)

The growing demand for surgical procedures, technological advancements, and strong healthcare infrastructure support the growth of the American anesthesia drugs market in the United States. As personalized medicine gains popularity, anesthesia regimens tailored to individual patient profiles are expected to gain traction in the country, requiring the development of novel anesthetic agents that offer improved safety with minimal side effects.

The demand for green anesthesia is expected to increase in the coming years due to growing interest in eco-conscious surgical practices. The anticipated expansion of ambulatory surgical centers in the United States, combined with increasing emphasis on AI-based drug administration systems, is expected to open new channels for growth for the key market players.

Key Players Landscape and Outlook

The key players in the market are focusing on launching new products in the United States in order to expand their presence in the country. For instance, in February 2024, Hikma Pharmaceuticals plc launched fentanyl citrate injection, USP, in 50mcg/mL doses and 25mcg/0.5mL doses. The product has been indicated as a narcotic analgesic supplement in regional or general anesthesia and as an anesthetic agent along with oxygen in patients who are at high risk, including those undergoing orthopedic and neurological procedures and open-heart surgeries. Such launches align with the increasing demand for anesthetic solutions in the United States and are ensuring the availability of essential medicines. By focusing on such launches, market players based in the United States are expected to increase their revenue while providing convenient drug administration solutions to healthcare professionals.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. United States Anesthesia Drugs Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Drugs Class
    • 4.2.1.1. Sevoflurane
    • 4.2.1.2. Propofol
    • 4.2.1.3. Dexmedetomidine
    • 4.2.1.4. Remifentanil
    • 4.2.1.5. Desflurane
    • 4.2.1.6. Midazolam
    • 4.2.1.7. Others
  • 4.2.2. By Route of Administration
    • 4.2.2.1. Intravenous
    • 4.2.2.2. Inhaled
  • 4.2.3. By Application
    • 4.2.3.1. Heart Surgeries
    • 4.2.3.2. Cancer
    • 4.2.3.3. General Surgery
    • 4.2.3.4. Knee and hip replacements
    • 4.2.3.5. Others
  • 4.2.4. By End-user
    • 4.2.4.1. Hospitals
    • 4.2.4.2. Ambulatory Surgical Centers
    • 4.2.4.3. Others
  • 4.2.5. By Region
    • 4.2.5.1. Northeast
    • 4.2.5.2. Midwest
    • 4.2.5.3. West
    • 4.2.5.4. South
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Drugs Class
  • 4.3.2. By Route of Administration
  • 4.3.3. By Application
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. Value Chain Analysis

6. Porter's Five Forces Analysis

7. PESTLE Analysis

8. Pricing Analysis

9. Market Dynamics

• 9.1. Market Drivers
• 9.2. Market Challenges

10. Market Trends and Developments

11. Clinical Trial Overview

12. Competitive Landscape

• 12.1. Competition Matrix of Top 5 Market Leaders
• 12.2. SWOT Analysis for Top 5 Players
• 12.3. Key Players Landscape for Top 10 Market Players
  • 12.3.1. Baxter International Inc.
    • 12.3.1.1. Company Details
    • 12.3.1.2. Key Management Personnel
    • 12.3.1.3. Products and Services
    • 12.3.1.4. Financials (As Reported)
    • 12.3.1.5. Key Market Focus and Geographical Presence
    • 12.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 12.3.2. AstraZeneca Pharmaceuticals, LP
  • 12.3.3. AbbVie Inc.
  • 12.3.4. B. Braun Medical Inc.
  • 12.3.5. Fresenius USA, Inc.
  • 12.3.6. Hospira Inc.
  • 12.3.7. Pfizer Inc.
  • 12.3.8. Aspen Pharmacare Holdings Limited
  • 12.3.9. Hikma Pharmaceuticals USA Inc.
  • 12.3.10. Novartis AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

13. Strategic Recommendations

14. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. United States Anesthesia Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 2. United States Anesthesia Drugs Market Share (%), By Drugs Class, 2018-2032F
• Figure 3. United States Anesthesia Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 4. United States Anesthesia Drugs Market Share (%), By Application, 2018-2032F
• Figure 5. United States Anesthesia Drugs Market Share (%), By End-user, 2018-2032F
• Figure 6. United States Anesthesia Drugs Market Share (%), By Region, 2018-2032F
• Figure 7. By Drugs Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 8. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 9. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 10. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 11. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024